20:49 , Dec 19, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation; pulmonary

INDICATION: Asthma; pulmonary fibrosis Mouse studies suggest an inhaled prodrug of a PI3K inhibitor could help treat asthma and pulmonary fibrosis. In mouse models of acute allergic asthma and chronic asthma, inhalation of a methylbenzoate-based...
22:27 , Jul 17, 2018 |  BC Week In Review  |  Clinical News

Cellectar's CLR 131 reduces tumor burden by 94% in patient with Waldenström's macroglobulinemia

Cellectar Biosciences Inc. (NASDAQ:CLRB) said a patient with advanced Waldenström's macroglobulinemia receiving CLR 131 in a Phase II trial achieved a 94% reduction in tumor burden and complete resolution in four of five targeted tumor...
00:28 , Oct 20, 2017 |  BC Week In Review  |  Financial News

Cellectar raises $7.8M in registered direct offering

On Oct. 12, Cellectar Biosciences Inc. (NASDAQ:CLRB) raised $7.8 million through the sale of shares and convertible stock in a registered direct offering. Cellectar sold 2 million common shares at $1.87 and 41 preferred shares...
19:47 , Oct 13, 2017 |  BC Week In Review  |  Company News

Cellectar and Pierre Fabre extend PDC deal

Cellectar Biosciences Inc. (NASDAQ:CLRB) and Pierre Fabre Group (Castres, France) extended a 2015 deal to develop phospholipid drug conjugates (PDC) to treat cancer. The companies said the extension will cover combining Pierre Fabre's cytotoxic payloads...
19:48 , Aug 18, 2017 |  BC Week In Review  |  Clinical News

Cellectar reports OS of 22.5 months in Phase I MM trial of CLR 131

Cellectar Biosciences Inc. (NASDAQ:CLRB) reported additional data from the first cohort of a Phase I trial in about 33 patients with relapsed or refractory multiple myeloma (MM) showing that a single dose of 12.5 mCi/m...
21:47 , Apr 4, 2017 |  BC Week In Review  |  Clinical News

CLR 131: Ph II started

Cellectar began an open-label, U.S. Phase II trial to evaluate a single dose of 25 mCi/m 2 IV CLR 131 plus once-weekly oral dexamethasone for up to 12 weeks in about 80 patients with hematologic...
17:41 , Mar 17, 2017 |  BC Week In Review  |  Company News

WARF, Cellectar deal

The foundation granted Cellectar rights to IP covering the method of use for Cellectar's CLR 131 to treat multiple myeloma (MM). As a result of the deal, the company gains remaining rights to exclusively develop...
22:15 , Jan 6, 2017 |  BioCentury  |  Finance

Good riddance

  Investors aren’t lamenting the end of 2016, but they are pinned between anxiety and optimism for the year ahead. The anxiety stems from uncertainty about U.S. government policies for healthcare under the new administration....
00:11 , Dec 1, 2016 |  BC Week In Review  |  Financial News

Cellectar completes follow-on

Cellectar raised $8 million through the sale 800,000 common shares at $1.50 and 68 shares of series A convertible preferred stock at $100,000 per share in follow-on underwritten by Ladenburg Thalmann and Aegis Capital. Investors...
00:40 , Nov 22, 2016 |  BC Week In Review  |  Financial News

Cellectar amends follow-on

Cellectar amended its follow-on and added Aegis Capital as an underwriter; Ladenburg Thalmann remains an underwriter. The company plans to sell up to $10 million in common stock, plus five-year warrants. Cellectar Biosciences Inc. (NASDAQ:CLRB),...